MicroRNAs in Cardiac Hypertrophy

• Published in: International journal of molecular sciences Vol. 20; no. 19; p. 4714
• Main Authors: Wehbe, Nadine, Nasser, Suzanne Awani, Pintus, Gianfranco, Badran, Adnan, Eid, Ali H, Baydoun, Elias
• Format: Journal Article
• Language: English
• Published: Switzerland MDPI AG 23-09-2019; MDPI
• Subjects: Animals; Biopsy; cardiac hypertrophy; Cardiac output; cardiac remodeling; Cardiomegaly - metabolism; Cardiomegaly - pathology; cardiomyocyte; Cardiomyocytes; Cell cycle; Cell division; Congestive heart failure; Gene expression; Genes; Heart attacks; Heart Failure - metabolism; Heart Failure - pathology; Humans; Hypertrophy; Insulin-like growth factors; Kinases; MicroRNAs; MicroRNAs - metabolism; miRNA; Organs; Physiology; Protein expression; Proteins; Review; Signal Transduction; therapeutic targets; Transcription factors; therapeutic targets; cardiac hypertrophy; MicroRNAs; cardiac remodeling; cardiomyocyte
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms20194714

Like other organs, the heart undergoes normal adaptive remodeling, such as cardiac hypertrophy, with age. This remodeling, however, is intensified under stress and pathological conditions. Cardiac remodeling could be beneficial for a short period of time, to maintain a normal cardiac output in times of need; however, chronic cardiac hypertrophy may lead to heart failure and death. MicroRNAs (miRNAs) are known to have a role in the regulation of cardiac hypertrophy. This paper reviews recent advances in the field of miRNAs and cardiac hypertrophy, highlighting the latest findings for targeted genes and involved signaling pathways. By targeting pro-hypertrophic genes and signaling pathways, some of these miRNAs alleviate cardiac hypertrophy, while others enhance it. Therefore, miRNAs represent very promising potential pharmacotherapeutic targets for the management and treatment of cardiac hypertrophy.